On February 20, 2026, the FDA issued a warning letter to Belle Health LLC (dba Belle) at their Draper, Utah address
(1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Patients should disclose a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney disease or other dehydration risks, use of diabetes medications such as insulin or sulfonylureas, pregnancy or plans for pregnancy, any personal or family history of medullary thyroid carcinoma or MEN2, and a history of diabetic retinopathy
From the starting dose of 2.5 mg , the next step is 5 mg weekly after 4 weeks
DOI: 10.3390/antiox10030364